At what dose does Phenylpiracetam produce psychosis?

Effects like psychosis are typically reported at common doses and above. A common oral dose of Phenylpiracetam is 100–200 mg.

What other substances cause psychosis?

Other substances documented to produce psychosis include 1P-ETH-LAD, Methamphetamine, 3,4-CTMP, 1P-LSD, Myristicin, and 35 more.

Psychosis from Phenylpiracetam — Detailed Guide

Q: Does Phenylpiracetam cause psychosis?

Yes. Psychosis is a documented cognitive effect of Phenylpiracetam. Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — characterized by firmly held false beliefs (delusions), perception of things that are not there (hallucinations), disorganized thought and speech, and a loss of the ability to distinguish internal mental events from external reality.

Psychosis from Phenylpiracetam

cognitiveStimulants, Nootropic

Psychosis + Phenylpiracetam

Effect category

cognitive

Substance class

Stimulants, Nootropic

Chemical class

Racetams

Routes of administration

oral

Other effects from Phenylpiracetam

Other substances causing this effect

Psychosis + Phenylpiracetam

Effect category

cognitive

Substance class

Stimulants, Nootropic

Chemical class

Racetams

Routes of administration

oral

Other Phenylpiracetam effects

Substances causing psychosis

Phenylpiracetam is known to produce psychosis, a cognitive effect. Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — characterized by firmly held false beliefs (delusions), perception of things that are not there (hallucinations), disorganized thought and speech, and a loss of the ability to distinguish internal mental events from external reality.

About Psychosis

Psychosis represents one of the most severe adverse cognitive outcomes associated with psychoactive substance use. It is not a single symptom but a syndrome — a constellation of related disruptions to perception, belief, and thought that collectively produce a state in which the person has lost meaningful contact with shared reality. The defining features include delusions (fixed false beliefs maintained with absolute conviction),hallucinations (perceiving things that are not present, across any sensory modality),thought disorder (disorganized, incoherent, or tangential thinking and speech), andloss of insight (the inability to recognize that one's perceptions and beliefs are abnormal).

What distinguishes psychosis from the altered perceptions produced by a "normal" psychedelic or dissociative experience is fundamentally about insight. A person having a psychedelic trip may see geometric patterns overlay their visual field, but they know they have taken a substance and that the patterns are drug-induced. A person experiencing psychosis may see the same patterns but believe they represent coded messages from a government surveillance network — and no amount of rational argument can shake this conviction. The loss of the ability to reality-test one's own perceptions is the critical threshold that separates an altered state from a psychotic one.

Substance-induced psychosis can arise through several pathways. Acute intoxication psychosis can occur with high doses of psychedelics, stimulants, cannabis, and deliriants — the sheer intensity of the altered state overwhelms the person's capacity to maintain orientation.Stimulant psychosis is particularly well-documented: extended use of amphetamines, methamphetamine, or cocaine, especially combined with sleep deprivation, can produce a paranoid psychotic state that closely resembles acute schizophrenia, complete with persecutory delusions, auditory hallucinations, and disorganized behavior.Cannabis-induced psychosis can occur in predisposed individuals, sometimes after a single heavy exposure.Withdrawal psychosis can accompany withdrawal from alcohol and benzodiazepines.

The relationship between substance use and psychosis is bidirectional and complex. Substances can trigger psychotic episodes in individuals with latent vulnerability (genetic predisposition to schizophrenia-spectrum disorders), can worsen existing psychotic conditions, and can produce transient psychotic states in individuals with no underlying vulnerability. Cannabis use during adolescence has been identified as a significant risk factor for the later development of psychotic disorders, with a dose-response relationship. However, most people who use these substances never experience psychosis, and the interaction between substance exposure and individual vulnerability is not well enough understood to predict individual risk.

Harm reduction note: Psychosis is a psychiatric emergency. If someone has lost contact with reality — believing things that are clearly not true, acting on hallucinated perceptions, unable to recognize that they are intoxicated — they need professional help. Do not attempt to argue them out of delusions, as this typically escalates agitation. Ensure physical safety, speak calmly and simply, and call for medical assistance. Individuals with a personal or family history of psychotic disorders should exercise extreme caution with all psychoactive substances, particularly cannabis, psychedelics, and stimulants.

How Phenylpiracetam Produces This Effect

Pharmacodynamics Phenylpiracetam is a racetam and is described as a stimulant. Racetams have a variety of different pharmacological activities and have varying effects. For example, phenylpiracetam is a stimulant, piracetam is a nootropic, and levetiracetam is an anticonvulsant. The mechanisms of action of most racetams, with some exceptions, are unknown.

Phenylpiracetam is a racemic mixture. (R)-Phenylpiracetam is the most active enantiomer and is much more potent in stimulating locomotor activity than (S)-phenylpiracetam, which is ineffective. However, (S)-phenylpiracetam retains some activity in most pharmacological tests. On the other hand, in one animal test, the passive avoidance test, (S)-phenylpiracetam appeared to be antagonistic of (R)-phenylpiracetam.

Dopamine reuptake inhibitor Experiments performed on Sprague-Dawley rats in a European patent for using phenylpiracetam to treat sleep disorders showed an increase in extracellular dopamine levels after administration. The patent asserts discovery of phenylpiracetam's action as a dopamine reuptake inhibitor as its basis.

The peculiarity of this invention compared to former treatment approaches for treating sleep disorders is the so far unknown therapeutic efficacy of (R)-phenylpiracetam, which is presumably based at least in part on the newly identified activity of (R)-phenylpiracetam as the dopamine re-uptake inhibitor

Both enantiomers of phenylpiracetam, (R)-phenylpiracetam and (S)-phenylpiracetam, have been described in peer-reviewed research as dopamine transporter (DAT) inhibitors in rodents, confirming the patent claim. Their actions at the norepinephrine transporter (NET) vary: (R)-phenylpiracetam acts as a dual norepinephrine–dopamine reuptake inhibitor (NDRI), with 11-fold lower affinity for the NET than for the DAT, whereas the (S)-enantiomer is selective for the DAT. However, whereas (R)-phenylpiracetam stimulates locomotor activity, (S)-phenylpiracetam does not do so. This variation in effects has also been seen with other dopamine reuptake inhibitors.

Other atypical dopamine reuptake inhibitors include modafinil, mesocarb (Sydnocarb), and solriamfetol.

Other actions Phenylpiracetam binds to α4β2 nicotinic acetylcholine receptors in the mouse brain cortex with an IC50Tooltip half-maximal inhibitory concentration of 5.86μM.

Racetams generally, but including phenylpiracetam, have been described as AMPA receptor potentiators.

Animal studies Research on animals has indicated that phenylpiracetam may have antiamnesic, antidepressant, anxiolytic, and anticonvulsant effects. Additional clinical research is necessary to determine whether these effects extend to humans.

Phenylpiracetam has been shown to reverse the sedative or depressant effects of the benzodiazepine diazepam, increases operant behavior, inhibits post-rotational nystagmus, prevents retrograde amnesia, and has anticonvulsant properties in animal models.

In Wistar rats with gravitational cerebral ischemia, phenylpiracetam reduced the extent of neuralgic deficiency manifestations, retained the locomotor, research, and memory functions, increased the survival rate, and lead to the favoring of local cerebral flow restoration upon the occlusion of carotid arteries to a greater extent than did piracetam.

In tests against a control, Sprague-Dawley rats given free access to less-preferred rat chow and trained to operate a lever repeatedly to obtain preferred rat chow performed additional work when given methylphenidate, dextroamphetamine, and phenylpiracetam. Rats administered 100mg/kg phenylpiracetam performed, on average, 375% more work than rats given placebo, and consumed little non-preferred rat chow. In comparison, rats administered 1mg/kg dextroamphetamine or 10mg/kg methylphenidate performed, on average, 150% and 170% more work respectively, and consumed half as much non-preferred rat chow.

Present data show that (R)-phenylpiracetam increases motivation, i.e., the work load, which animals are willing to perform to obtain more rewarding food. At the same time consumption of freely available normal food does not increase. Generally this indicates that (R)-phenylpiracetam increase motivation [...] The effect of (R)-phenylpiracetam is much stronger than that of methylphenidate and amphetamine.

Pharmacokinetics The pharmacokinetics of phenylpiracetam in humans are unpublished. In any case, the drug is described as having an oral bioavailability of approximately 100%, as having an onset of action of less than 1hour, as not being metabolized, as being excreted unchanged about 40% in urine and 60% in bile and sweat, and as having an elimination half-life of 3 to 5hours. In rodents, its absorption occurs within 1hour with oral administration or intramuscular injection and its elimination half-life is 2.5 to 3hours.

Phenylpiracetam can be administered via oral. The route of administration can influence both the onset and intensity of psychosis.

Psychosis from Phenylpiracetam

Psychosis + Phenylpiracetam

Psychosis + Phenylpiracetam

About Psychosis

How Phenylpiracetam Produces This Effect

Dosage Context

oral

Other Substances That Cause Psychosis (40)

Cannabinoid

Deliriant

Depressant

Dissociatives

Dissociatives, Psychedelic

Entactogen, Stimulants

Essential nutrient, Neurotransmitter cofactor

Neurotransmitter

Psychedelic

Stimulants

See Also

Frequently Asked Questions

Psychosis from Phenylpiracetam

Psychosis + Phenylpiracetam

Psychosis + Phenylpiracetam

About Psychosis

How Phenylpiracetam Produces This Effect

Dosage Context

oral

Other Effects from Phenylpiracetam (28)

Other Substances That Cause Psychosis (40)

Cannabinoid

Deliriant

Depressant

Dissociatives

Dissociatives, Psychedelic

Entactogen, Stimulants

Essential nutrient, Neurotransmitter cofactor

Neurotransmitter

Psychedelic

Stimulants

See Also

Frequently Asked Questions